With new regimens emerging as viable options for neoadjuvant therapy, clinicians should be aware of the changing landscape in initial cutaneous melanoma treatment options. It will be essential for the clinician to identify patients who would benefit from neoadjuvant intervention versus a more traditional surgical or systemic therapy approach.